Search
Xencor Inc
XNCRAdd to Watchlist
14.924USD
-0.456-2.96%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.96%
5 Days
+3.28%
1 Month
+26.48%
6 Months
-2.52%
Year to Date
-2.52%
1 Year
+84.93%
Key Figures
15.390Open
15.720High
534.95KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.72%Turnover Ratio
15.380Prev. Close
14.890Low
5.29MTurnover
LossP/E Static
2.14P/B
0.00%Div Yield TTM
-21.01%ROA
18.69052wk High
0.84Volume Ratio
-232.62MNet Profit
74.06MShares
-2.2942EPS TTM
0.92Beta
-29.84%ROE
6.92052wk Low
5.40%Amplitude
100.00%Gross Margin
1.11BMarket Cap
10.12Reward/Risk
3.68%Risk Rate
TradingKey Stock Score of Xencor Inc
Currency: USD Updated: 2026-07-01Key Insights
Xencor Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 73 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.82.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xencor Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Xencor Inc Highlights
StrengthsRisks
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Fairly Valued
The company’s latest PE is -6.70, at a medium 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 45.09K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
29.818
Target Price
+85.21%
Upside Space
Xencor Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xencor Inc Info
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Ticker SymbolXNCR
CompanyXencor Inc
CEODahiyat (Bassil I)
Websitehttps://xencor.com/
Related Instruments
+1.33%
+2.83%
+5.32%
+3.44%
+2.26%
+3.06%
+3.01%
+2.95%
+3.47%
+1.82%
+4.20%
+1.56%
+3.97%
+3.16%
+2.05%
0.00%
+3.30%
+3.10%
+0.25%
+4.50%Popular Instruments
52768.900
+514.600 (+0.98%)
29262.200
-537.100 (-1.80%)
7465.800
-9.700 (-0.13%)
14764.000
-591.000 (-3.85%)
67924.000
-1561.000 (-2.25%)
6350.500
+75.100 (+1.20%)
68.354
+0.386 (+0.57%)
308.310
+13.930 (+4.73%)
193.510
-4.070 (-2.06%)
4117.600
+86.830 (+2.15%)
FAQs
What is the current price of Xencor Inc (XNCR)?
The current price of Xencor Inc (XNCR) is 15.38.
What is the symbol of Xencor Inc?
The ticker symbol of Xencor Inc is XNCR.
What is the 52-week high of Xencor Inc?
The 52-week high of Xencor Inc is 18.69.
What is the 52-week low of Xencor Inc?
The 52-week low of Xencor Inc is 6.92.
What is the market capitalization of Xencor Inc?
The market capitalization of Xencor Inc is 1.14B.
Is Xencor Inc (XNCR) currently rated as Buy, Hold, or Sell?
According to analysts, Xencor Inc (XNCR) has an overall rating of Buy, with a price target of 29.82.
What is the Earnings Per Share (EPS TTM) of Xencor Inc (XNCR)?
The Earnings Per Share (EPS TTM) of Xencor Inc (XNCR) is -1.24.